Navigation Links
ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study
Date:9/15/2010

s treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma commercializes Cinryze™ (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE, and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Forward Looking Statements

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide the Company's current expectations or forecasts of future events. Forward-looking statements in this press release include statements regarding the timing and nature of ViroPharma's clinical development programs, including statements that VP20621 may potentially protect a patient from colonization with toxin-producing strains of C. difficile and VP20621 may significantly reduce the incidence of recurrent disease for patients with CDI. Our actual results could differ materially from those results expressed in, or implied
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Corporation (NASDAQ: TECH ) announced today that ... new Simple Plex platform through its Proteins Platform division ... of the previously acquired CyPlex instrument platform from CyVek. ... immunoassay technology which integrates an innovatively designed microfluidic cartridge ...
(Date:1/22/2015)... PARK, Calif. , Jan. 22, 2015 Increasing ... the continued consolidation of localization purchasing in 2015, says ... According to a recent study by market research ... chose a single-source solution for their translation and localization ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... addition of the "Microbiology Testing/Clinical Microbiology Market ... Global Forecast to 2019" report to their ... wide array of techniques for the detection of ...
Breaking Medicine Technology:Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 3
... Corporation (Nasdaq: DRRX ) today reported that King ... Inc. (Nasdaq: PTIE ) have announced that King ... the U.S. Food and Drug Administration (FDA) in response to ... 2008.  This is a Class 2 resubmission with a six ...
... During ICMS (International Cellular Medicine Society www.cellmedicinesociety.org ) ... Conference held on November 12, 2010 in Las Vegas, ... of diabetes gangrene recovered from foot ulcer through stem ... ) Patient, Sun Rae Cho (age 72 ...
Cached Medicine Technology:REMOXY® New Drug Application Resubmitted 2REMOXY® New Drug Application Resubmitted 3New Hope for Saving Diabetic Foot from Amputation 2
(Date:1/22/2015)... Nashville, TN (PRWEB) January 22, 2015 Gabe’s Chemo ... Chemo Duck App, the first app ever created for kids with ... all Apple phones and devices, is filled with enjoyable games to ... life and treatments. The free app helps to keep kids entertained, ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 Angelweddingdress is a ... business invites its customers to follow it on Facebook, Twitter, ... a Valentine’s Day gift. Angelweddingdress draws a lottery every week. ... Sale to Feb. 28, 2015. Click Angelweddingdress homepage ...
(Date:1/22/2015)... 2015 Juvent Sports ( http://www.juventsports.com ) ... PGA Merchandise Show to bestow a Juvent Sports Achievement ... golfer, Arlene McKitrick. The award commemorated and congratulated McKitrick ... win. She won her first amateur tournament in 1979 ...
(Date:1/22/2015)... over 20 years, Dr. David Cruz of Cruz Chiropractic Care ... just about every type of injury that can result from car ... twenty-plus years, the team at Doctors on Liens has ... doctor. With the combined breadth of experience between the ...
(Date:1/22/2015)... Yesterday, Senator Holly Mitchell (D-Los ... Olsen (R-Modesto) were honored by the California Healthcare ... biomedical science, medical device and pharmaceutical innovation in ... “2014 Life Sciences Champion” award from CHI President ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
... , FRIDAY, Sept. 23 (HealthDay News) -- Many studies have ... day is heart-healthy, and much of the benefit has been ... wine called polyphenols. But a new Dutch study suggests ... lower blood pressure after all. Study author Ilse ...
... the longest-running trial comparing tamoxifen with the aromatase ... the test of time and continues to prevent ... death in post-menopausal women with hormone receptor-positive early ... at the 2011 European Multidisciplinary Cancer Congress [1], ...
... obesity, has been linked to the development of asthma in ... at the European Respiratory Society,s Annual Congress in Amsterdam today ... factor for the disease. Excess abdominal fat has been ... and heart disease, but there has been little focus on ...
... Stockholm, Sweden: Many prostate cancer patients develop bone metastases, ... Now the first large randomised Phase III trial of ... a single dose of the drug is as good ... treatment for bone metastases. Results of the trial were ...
... the devastating personal and financial impact that chronic obstructive ... The findings, which are to be presented today ... Congress in Amsterdam, provides new perspectives on the personal ... 45-65 year age group. 80% reported ...
... Stockholm, Sweden: The first randomised trial to investigate the ... for the initial treatment of HER2- (human epidermal ... that it makes a significant difference to the time ... Hurvitz, one of the trial investigators, will tell the ...
Cached Medicine News:Health News:Antioxidants Not Behind Red Wine's Healthy Effect on Heart: Study 2Health News:Aromatase inhibitor letrozole guards against breast cancer relapse for up to 8 years 2Health News:Aromatase inhibitor letrozole guards against breast cancer relapse for up to 8 years 3Health News:Aromatase inhibitor letrozole guards against breast cancer relapse for up to 8 years 4Health News:'Belly fat' linked to development of asthma 2Health News:Bone-strengthening drug gives pain relief in prostate cancer bone metastases 2Health News:Bone-strengthening drug gives pain relief in prostate cancer bone metastases 3Health News:Study sheds light on the impact of COPD on working aged populations 2Health News:Phase II study shows new cancer drug combination significantly delays breast cancer progression 2Health News:Phase II study shows new cancer drug combination significantly delays breast cancer progression 3
The Link SP II Hip stem for cemented revisions...
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
Quatroloc Revision Hip System...
Severe revision options for the knee and hip...
Medicine Products: